Table 2 Diagnostic and predictive moels built using biomarkers.

From: Clinical use of artificial intelligence in endometriosis: a scoping review

AI methods used

Authors [ref.]

Stage of endometriosis

Type of endometriosis

Sample size

Inputs used

Method accuracy

Random Forest

Bendifallah et al.35

rASRM Class I–II and Class III–IV

Not specified

200 patients (153 endometriosis, 47 controls)

86 miRNAs composing a diagnostic blood signature

SE = 96.8%

SP = 100%

 

Knific et al.31

All four stages of endometriosisa

Not specified

210 patients (116 endometriosis, 94 controls)

Proteins ratios for the following: CTACK/MCP-3, MCP-3/CTACK, CCL11/I-309, X6Ckine/MCP-1, CTACK/SCYB16, Gro-alpha/CTACK

SE = NR

SP = NR

Logistic Regression

Bendifallah et al.35

rASRM Class I–II and Class III–IV

Not specified

200 patients (153 endometriosis, 47 controls)

86 miRNAs composing a diagnostic blood signature

SE = 96.8%

SP = 100%

 

Vodolazkaia et al.34

Not specified

U/S negative endometriosis

353 EDTA samples (232 endometriosis, 121 controls)

VEGF, Annexin V, CA-125, glycodelin, sICAM-1

SE = 82%

SP = 75%

eXtreme Gradient Boost

Bendifallah et al.35

rASRM Class I–II and Class III–IV

Not specified

200 patients (153 endometriosis, 47 controls)

86 miRNAs composing a diagnostic blood signature

SE = 90.3%

SP = 100%

AdaBoost

Bendifallah et al.35

rASRM Class I–II and Class III–IV

Not specified

200 patients (153 endometriosis, 47 controls)

86 miRNAs composing a diagnostic blood signature

SE = 96.8%

SP = 100%

Support Vector Machines

Dominguez et al.33

Not specified

Ovarian endometriosis

35 patients (12 endometriosis, 23 controls)

123 differentially expressed metabolites in endometrial fluid

SE = 58.3%

SP = 100%

Least Squares Support Vector Machines

Vodolazkaia et al.34

Not specified

U/S negative endometriosis

353 EDTA samples (232 endometriosis, 121 controls)

VEGF, Annexin V, CA-125, sICAM-1

SE = 82%

SP = 75%

  1. rASRM revised American Society of Reproductive Medicine, NR not reported, U/S ultrasound, CTACK cutaneous T cell-attracting chemokine, MCP-3 monocyte chemotactic protein 3, CCL-11 C-C motif chemokine ligand 11, I-309 chemokine ligand 1, X6Ckine C-C motif chemokine 21, MCP-1 monocyte chemoattractant protein 1, SCYB16 chemokine ligand 16, Gro-alpha growth regulated oncogene-alpha, VEGF vascular endothelial growth factor, CA-125 cancer antigen 125, sICAM-1 soluble intercellular adhesion molecule-1, SE sensitivity, SP specificity.
  2. aMinimal, mild, moderate and severe stages of endometriosis were included.
Back to article page